Inhaled Nitric Oxide for Prevention of Bronchopulmonary Dysplasia in Premature Infants
EUNO Trial · Lancet · 2010
The EUNO trial was a multicentre, double-blind, randomized placebo-controlled trial involving 800 extremely preterm infants (24–28⁶/₇ weeks' gestation) with respiratory distress syndrome. It evaluated whether early administration of low-dose inhaled nitric oxide (iNO) at 5 ppm for 7–21 days could prevent bronchopulmonary dysplasia (BPD). Survival without BPD at 36 weeks' postmenstrual age was similar in the iNO and placebo groups (65% vs 66%). No significant improvements in survival, BPD, or neurological outcomes were demonstrated. The findings do not support routine early iNO administration for BPD prevention in extremely preterm infants
Survival without BPD occurred in 65% (iNO group) vs 66% (placebo group), showing no significant benefit.
Survival at 36 weeks occurred in 86% (iNO group) vs 90% (placebo group), with no statistically significant difference.
BPD occurred in 24% (iNO group) vs 27% (placebo group) among assessed survivors, without significant reduction.
No significant improvement in neurological outcomes was demonstrated.
Early low-dose iNO failed to prevent BPD or improve survival in extremely preterm infants.
The findings challenged routine prophylactic iNO use for BPD prevention
Infants with severe respiratory failure were excluded, limiting generalizability.
Only one iNO dose (5 ppm) was evaluated.
Treatment was initiated within 24 hours, leaving the effects of later initiation uncertain.
The trial was not designed to evaluate iNO specifically for pulmonary hypertension.
The primary study focused on short-term outcomes at 36 weeks' postmenstrual age.
Subgroup analyses could not reliably establish which infants might benefit
Early low-dose iNO does not significantly improve survival without BPD in extremely preterm infants.
Routine prophylactic iNO is not recommended for preventing BPD.
Improvements in pulmonary vasodilation do not necessarily translate into improved long-term respiratory outcomes.
The findings should not be extrapolated to selected preterm infants with documented pulmonary hypertension.
The EUNO trial provides strong evidence against routine early iNO administration solely for BPD prevention